Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer

Fig. 5

Effects of RC48 and CM combinational treatment on global gene expression in OC cells. Gene expression studies were performed using RNA-Seq in A2780 cells and OVCAR-3 cells treated with VEH, 4 μg/mL RC48, 2.5 µM CM or COM for 48 h. Each group consisted of triplicate samples. A, B The expression of DEGs in A2780 (A) and OVCAR-3 (B) cells between the VEH and COM groups is shown. Upregulated genes are depicted in red, while downregulated genes are depicted in green. Gene expression values are presented as the log10 of tag counts. E, F The number of overlapping DEGs in RC48, CM, and COM treated cells compared to VEH-treated cells is displayed. G, H Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was performed on DEGs in COM-treated samples compared to VEH-treated samples. I, J Analysis of the PI3K/AKT signaling pathway and cell cycle-related proteins. GAPDH was used as the loading control. K The effect of 5 µM AKTi1/2 and 5 µM SC79 on the combined effect of RC48 and CM in OC cells was assessed using Cell Titer-Glo cytotoxicity assays. Data represent the mean ± SEM of at least three independent experiments, and statistical significance was assessed using an unpaired T-test (*P < 0.05, **P < 0.01, ***p < 0.001)

Back to article page